Revolution Medicines (NASDAQ:RVMD – Get Free Report) and MacroGenics (NASDAQ:MGNX – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.
Profitability
This table compares Revolution Medicines and MacroGenics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Revolution Medicines | N/A | -84.51% | -51.97% |
| MacroGenics | -45.37% | -246.62% | -31.36% |
Analyst Ratings
This is a summary of recent ratings and price targets for Revolution Medicines and MacroGenics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Revolution Medicines | 1 | 1 | 21 | 1 | 2.92 |
| MacroGenics | 1 | 1 | 3 | 0 | 2.40 |
Revolution Medicines presently has a consensus price target of $262.75, suggesting a potential upside of 63.57%. MacroGenics has a consensus price target of $8.50, suggesting a potential upside of 333.67%. Given MacroGenics’ higher probable upside, analysts plainly believe MacroGenics is more favorable than Revolution Medicines.
Risk & Volatility
Revolution Medicines has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.
Insider & Institutional Ownership
94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 13.6% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Revolution Medicines and MacroGenics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Revolution Medicines | $197.56 million | 175.86 | -$1.13 billion | ($9.11) | -17.63 |
| MacroGenics | $149.50 million | 0.84 | -$74.62 million | ($0.81) | -2.42 |
MacroGenics has lower revenue, but higher earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.
Summary
Revolution Medicines beats MacroGenics on 8 of the 15 factors compared between the two stocks.
About Revolution Medicines
Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.
About MacroGenics
MacroGenics, Inc. is a biotechnology company focused on discovering and developing antibody-based medicines, primarily for cancer. Founded in 2000 and headquartered in Rockville, Maryland, the company works on its own drug candidates and collaborates with other pharmaceutical and biotechnology companies. Its research uses antibody-engineering technologies, including platforms designed to engage immune cells against tumors and to deliver therapeutic payloads to cancer cells. MacroGenics’ portfolio has included margetuximab, marketed as Margenza, an antibody treatment approved in the United States for certain patients with HER2-positive metastatic breast cancer.
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
